Related Experiment Videos
Insights
Most hemorrhoid patients require minimal treatment, with many avoiding prescription drugs. Further research into laxative use could reveal significant cost savings for preventing recurrent hemorrhoid cases.
Area of Science:
- Gastroenterology
- Health Economics
Background:
- Hemorrhoids are a common condition requiring medical and surgical interventions.
- Understanding treatment patterns and associated costs is crucial for healthcare management.
Purpose of the Study:
- To analyze the treatment patterns and healthcare resource utilization for patients with routine hemorrhoids.
- To explore potential cost savings related to preventative measures, specifically laxative use.
Main Methods:
- Analysis of office visits, prescriptions, and procedures for hemorrhoid patients.
- Examination of treatment modalities, including surgical interventions and prescription drug use.
- Assessment of direct surgical charges as a component of overall medical costs.
Main Results:
- Patients with routine hemorrhoids averaged 1.25 office visits and 1.38 procedures annually.
- 63.9% of patients received treatment without prescription drugs; 72% of costs were surgical.
- Prescription laxative use was low (1.5%), but over-the-counter (OTC) use was not assessed.
Conclusions:
- Routine hemorrhoid treatment often involves outpatient procedures rather than extensive prescription drug use.
- Significant cost savings may be achievable through the appropriate use of OTC stool softeners and laxatives for prevention.
- Further investigation into prescribing patterns for laxatives is warranted to confirm cost-saving potential.
Abstract:
The patients with routine, easiest-to-treat hemorrhoids average 1.25 office visits, 0.80 prescriptions, and 1.38 medical/surgical procedures during the course of a year. About 63.9% of all PTEs were treated without the use of prescription drugs. This patient group did not receive any hospital admissions or professional inpatient services. Hemorrhoid surgery was performed at an average rate of 1.37 times per PTE on an out-patient basis. Seventy-two percent of the overall medical charges for hemorrhoid treatment are direct surgical charges. Of the PTEs treated with a single drug group, only 1.5% are treated with a prescription laxative. However, the use of OTC stool softeners and laxatives were not measured in this analysis. Thus, an exact measurement of cost savings associated with appropriate use of softeners/laxatives for the prevention of recurrent hemorrhoids could not be determined. Considering the potential cost savings of using laxatives for prevention of hemorrhoids, further investigation of the prescribing patterns of this specialty may prove useful.